Apogee Therapeutics Inc

Apogee Therapeutics insider sales, clinical milestones, and FDA fast‑track status: learn how CFO trades, phase 2b efficacy, and cash runway shape future growth prospects.

Apogee Therapeutics CFO Jane Henderson sells 2,000 shares at $85—insider trend shows steady profit‑taking amid a $350 M offering and rising confidence in biotech growth.

Apogee Therapeutics insider trades reveal CMO confidence in Phase 2 milestones, fast‑track ADC pipeline, and value‑based commercialization strategy.

Apogee Therapeutics CFO insider sales reveal disciplined liquidity management, not looming distress, and highlight the firm’s biotech strategy, R&D focus, and market positioning in value‑based care.